Literature DB >> 19231981

A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia.

Lavnish Joshi1, Simon R J Taylor, Oliver Large, Sophie Yacoub, Susan Lightman.   

Abstract

A patient undergoing chemotherapy for treatment of acute lymphocytic leukemia developed septicemia that was treated with linezolid for 16 days. The patient subsequently reported reduced vision in both eyes and was found to have bilateral optic neuropathy. After the discontinuation of linezolid treatment, both the optic neuropathy and visual impairment resolved without sequelae.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19231981     DOI： 10.1086/597298

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

2.  Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.

Authors:  Michael J Schlosser; Hiromi Hosako; Ann Radovsky; Mark T Butt; Dragomir Draganov; Jenifer Vija; Frederick Oleson
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

3.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

4.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

Review 5.  A Review of Mitochondrial Optic Neuropathies: From Inherited to Acquired Forms.

Authors:  Yasmine L Pilz; Sherry J Bass; Jerome Sherman
Journal:  J Optom       Date:  2016-12-28

Review 6.  Clinical Overview of Leber Hereditary Optic Neuropathy.

Authors:  Almina Stramkauskaitė; Ieva Povilaitytė; Brigita Glebauskienė; Rasa Liutkevičienė
Journal:  Acta Med Litu       Date:  2022-06-29

Review 7.  Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency.

Authors:  Kenneth A Myers; Ana Nikolic; Kenneth Romanchuk; Ezekiel Weis; Marie-Anne Brundler; Lucie Lafay-Cousin; Fiona Costello
Journal:  Neurooncol Pract       Date:  2016-12-09

8.  Linezolid-induced optic neuropathy.

Authors:  Divya Karuppannasamy; Andavar Raghuram; Devisundaram Sundar
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848

9.  Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.

Authors:  Salil Mehta; Mrinalini Das; Chinmay Laxmeshwar; Sylvie Jonckheere; Sein Sein Thi; Petros Isaakidis
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

10.  Safety of long-term use of linezolid: results of an open-label study.

Authors:  Jose A Vazquez; Anthony C Arnold; Robert N Swanson; Pinaki Biswas; Matteo Bassetti
Journal:  Ther Clin Risk Manag       Date:  2016-09-01       Impact factor: 2.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.